Current status of biosimilars in the treatment of inflammatory bowel diseases
Intestinal Research
;
: 15-20, 2016.
Artigo
em Inglês
| WPRIM
| ID: wpr-77867
ABSTRACT
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden on National Healthcare Systems. The development of first biosimilar to infliximab, CT-P13 (Remsima; Celltrion Inc., Incheon, Korea and Inflextra; Hospiral, Lake Forest, Illinois, USA) has become another way to decrease the medical care cost and increase patient treatment option, but, actual equivalence of efficacy and safety of CT-P13 was investigated in rheumatic diseases only. The extrapolation of outcome from rheumatic trials to IBD and the interchangeability of CT-P13 with infliximab have come to be a matter of concern. Two recent retrospective studies reported the similarity of CT-P13 in terms of efficacy and safety. Infliximab biosimilars may be promising new treatment options for IBD patients, however, well-designed, prospective randomized non-inferiority trials should be needed to confidently integrate infliximab biosimilars into IBD treatment.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmácia
/
Árvores
/
Terapia Biológica
/
Doenças Inflamatórias Intestinais
/
Colite Ulcerativa
/
Doença de Crohn
/
Lagos
/
Illinois
/
Doenças Reumáticas
/
Estudos Prospectivos
Tipo de estudo:
Estudo observacional
Limite:
Humanos
País/Região como assunto:
América do Norte
/
Ásia
Idioma:
Inglês
Revista:
Intestinal Research
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS